Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 14 of 14

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16	From Day 1 to Day 112	All treated participants~Note: data not reported due to privacy reasons	percentage	MEAN
PRIMARY	Number of Participants With Adverse Events (AEs)	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Serious Adverse Events (SAEs)	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Injection Site Reactions	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Adverse Events Leading to Discontinuation	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Deaths	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Marked Laboratory Abnormalities	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Vital Sign Abnormalities	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Electrocardiogram (ECG) Abnormalities	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Number of Participants With Physical Examination Abnormalities	From first dose to date of last dose plus 30 days	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
PRIMARY	Mean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)	From Day 1 to Day 112	All treated participants with DXA data at baseline and 6 months~Note: data not reported due to privacy reasons	Percentage	MEAN
SECONDARY	Geometric Mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112	From Day 1 to Day 112	All treated participants~Note: data not reported due to privacy reasons	ng/mL	GEOMETRIC_MEAN
SECONDARY	Number of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142	From Day 1 to Day 142	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER
SECONDARY	Number of Participants With Positive Anti-FGF21 Antibody Response at Day 142	From Day 1 to Day 142	All treated participants~Note: data not reported due to privacy reasons	Participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03400163/outcomes

API reference For AI assistants